AWAKN LIFE SCIENCES CORP - AWKNF STOCK NEWS

Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has entered into a commercial collaboration agreement with Graft Polymer (UK) Plc (LON: GPL) to develop Awakn's novel aminoindane new chemical entity series programme. The collaboration aims to develop potential treatments for trauma-related mental health disorders, particularly post-traumatic stress disorder (PTSD).

Key points of the agreement include:

• Graft will initially contribute £300,000 and expertise in novel drug delivery systems
• Awakn will contribute intellectual property and development expertise
• Future funding will be split equally between the companies
• Graft will receive a 40% royalty of future net income generated by the Aminoindane NCEs
• The program will be led by Awakn's Chief Scientific Officer, Prof. David Nutt

Awakn Life Sciences announced the closing of a second tranche of its non-brokered private placement, raising an additional $394,285 by issuing 857,142 units at $0.46 per unit.

Each unit consists of one common share and 0.75 of a common share purchase warrant, allowing purchase of one common share at $0.63 for five years. The proceeds will fund the company's working capital. Securities from the offering are subject to a four-month plus one-day hold period.

The offering is not registered under the U.S. Securities Act and cannot be sold within the United States without proper registration or exemption.

Awakn Life Sciences Corp. is facing a potential cease-trade order due to the late filing of its audited annual financial statements and MD&A for the financial year ended January 31, 2024. The company delisted its common shares from Cboe Canada and listed them on the Canadian Securities Exchange, resulting in a condensed timeline for filing. If the financial statements are not filed by May 7, 2024, a cease-trade order may be issued by the Ontario Securities Commission. Awakn has applied for a management cease trade order to allow non-directors, officers, and insiders to continue trading in their securities.

Awakn Life Sciences Corp. has closed the first tranche of a private placement, raising $131,428 through the issuance of 285,714 units at $0.46 per unit. The funds will be used for general working capital. The offering is subject to regulatory approvals and securities legislation.

Awakn Life Sciences Corp. announces a Licensing Partnership with Rivus Wellness and Research Institute for its proprietary treatment protocol, Awakn Kare, targeting Alcohol Use Disorder. The agreement aims to improve addiction treatment success rates in the U.S. southern states. Additionally, Awakn discloses details of a non-brokered private placement financing for gross proceeds of up to $4,000,000.

Awakn Life Sciences Corp. (AWKNF) has received approval to list its common shares on the Canadian Securities Exchange under the symbol 'AWKN' with a focus on developing medication-assisted treatments for Alcohol Use Disorder.

Awakn Life Sciences Corp. is set to list its common shares on the Canadian Securities Exchange (CSE) after receiving conditional approval, with the intention to delist from Cboe Canada. The company has also closed the fifth tranche of a non-brokered private placement financing, issuing 142,857 units for gross proceeds of $65,714 for this tranche and $3,030,377 in total for the Offering to date.

Awakn Life Sciences Corp. has designated program AWKN-002 for Alcohol Use Disorders in the US market, focusing on a proprietary S-ketamine formulation administered sublingually via an oral thin film. The company has successfully completed an investigative study on the dissociative effect and reduction in alcohol cravings of the S-ketamine OTF, leading to the designation of AWKN-002. Additionally, Awakn has signed a global licensing agreement with LTS Lohmann Therapie-Systeme AG for a proprietary S-ketamine OTF, ensuring strong intellectual property protection and potential to rapidly progress to late clinical stage trials.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces global licensing agreement with LTS Lohmann Therapie-Systeme AG for a proprietary S-ketamine formulation to treat addiction, anxiety, and eating disorders. The agreement includes exclusive rights, access to Phase 1 data, and patents filed in the US and key international markets. The sublingual S-ketamine formulation offers potential advancements in addiction treatment, with faster onset of action, precise dosing, and reduced adverse effects. The agreement also includes terms related to milestone payments, royalties, and commercial manufacturing of the drug product by LTS.